A detailed history of Captrust Financial Advisors transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 49,606 shares of IOVA stock, worth $371,548. This represents 0.0% of its overall portfolio holdings.

Number of Shares
49,606
Previous 25,435 95.03%
Holding current value
$371,548
Previous $203,000 129.06%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.28 - $11.9 $175,964 - $287,634
24,171 Added 95.03%
49,606 $465,000
Q2 2024

Aug 14, 2024

SELL
$7.78 - $14.19 $191,302 - $348,917
-24,589 Reduced 49.15%
25,435 $203,000
Q1 2024

May 15, 2024

BUY
$7.59 - $17.47 $110,480 - $254,293
14,556 Added 41.04%
50,024 $741,000
Q4 2023

Feb 14, 2024

BUY
$3.3 - $8.89 $117,044 - $315,310
35,468 New
35,468 $288,000
Q2 2022

Aug 23, 2022

SELL
$6.38 - $18.33 $1,837 - $5,279
-288 Reduced 16.35%
1,474 $16,000
Q2 2022

Aug 16, 2022

SELL
$6.38 - $18.33 $331 - $953
-52 Reduced 2.87%
1,762 $19,000
Q1 2022

May 16, 2022

BUY
$12.38 - $19.1 $6,140 - $9,473
496 Added 37.63%
1,814 $30,000
Q4 2021

Feb 14, 2022

SELL
$16.55 - $27.63 $1,340 - $2,238
-81 Reduced 5.79%
1,318 $25,000
Q3 2021

Nov 16, 2021

BUY
$20.35 - $26.63 $6,898 - $9,027
339 Added 31.98%
1,399 $34,000
Q2 2021

Aug 16, 2021

BUY
$16.33 - $33.07 $1,322 - $2,678
81 Added 8.27%
1,060 $28,000
Q1 2021

May 17, 2021

BUY
$28.67 - $52.59 $7,998 - $14,672
279 Added 39.86%
979 $31,000
Q2 2020

Aug 14, 2020

BUY
$27.21 - $41.0 $19,047 - $28,700
700 New
700 $20,000

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.18B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.